ProGen appoints Kim Jong-kyun as new CEO
상태바
ProGen appoints Kim Jong-kyun as new CEO
  • Kevin Lee 기자
  • 승인 2022.08.23 16:11
  • 댓글 0
이 기사를 공유합니다

Kim has been in charge of the development of autoimmune disease treatments

ProGen, a new drug development company, announced on Aug. 22 that it has appointed President Kim Jong-kyun as its new CEO.

Since 1994, Kim has been in charge of research and development of innovative new drugs at Yuhan Corporation, serving as the head of the Global New Drug Center and the head of the R&D Strategy Office.

Kim Jong-kyun, new CEO of ProGen
Kim Jong-kyun, new CEO of ProGen

This year, he joined ProGen as president and oversaw the development of autoimmune disease treatments and immuno-cancer drugs. ProGen plans to speed up the development of new drugs led by CEO Kim.

Meanwhile, Dr. Jin Hyun-tak, who has served as CEO, will focus on developing new drugs after resigning as CEO, the company explained.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.
주요기사